5
Orphan Designations
0 approved, 5 designated
2
FDA Approvals
Latest: TALICIA (2019)
0
Active Trials
7
Rare Diseases
across 14 areas
0
News (30d)
Quiet
RedHill Biopharma Ltd is a company with 5 orphan drug designations across 7 rare diseases, including 2 FDA-approved therapies. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Crohn disease | clarithromycin, rifabutin, clofazimine | Des.TrialAppr. |
| cholangiocarcinoma | 4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide | Des.TrialAppr. |
| malignant carotid body paraganglioma | clarithromycin, rifabutin, and clofazimine | Des.TrialAppr. |
| malignant pancreatic neoplasm | upamostat | Des.TrialAppr. |
| neuroblastoma | Opaganib | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | clarithromycin, rifabutin, and clofazimine | Des.TrialAppr. |
| treatment-refractory schizophrenia | clarithromycin, rifabutin, and clofazimine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
99
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
99
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
1
affecting portfolio